MS Market is Estimated to Be Worth Almost US$8 Billion in 2008, With a Growth Rate of 10.6% Year-on-Year
Research and Markets (http://www.researchandmarkets.com/research/f0d42d/cns_drug_discoveri) has announced the addition of the “CNS Drug Discoveries: Multiple Sclerosis Chapter” report to their offering.
This chapter of CNS Drug Discoveries focuses on the multiple sclerosis market.
With the launch of up to 12 new disease-modifying agents, three vaccines and one novel drug designed to treat the symptoms of multiple sclerosis (MS) and improve quality of life, the MS market is in an exciting phase of evolution.
The MS market is estimated to be worth almost US$8 billion in 2008, with a growth rate of 10.6% year-on-year. It is the fifth largest segment of the CNS markets considered in this report and has attracted considerable R&D investment from the big pharmaceutical companies, biotechnology companies and specialty pharma.
Over the next six years a number of oral agents are expected to be launched that could drastically change the way in which MS patients are treated. These include: Novartis’ fingolimod, Teva’s laquinimod, Merck KGaA’s Mylinax (cladribine), sanofi-aventis’ teriflunomide and Biogen Idec’s BG-12 in Phase III development, and GSK/Mitsubishi Tanabe Pharma’s firategrast, MediciNova’s ibudilast and Biogen/UCB’s CDP323 in Phase II development.
Three companies have taken on the ambitious task of developing vaccines to treat MS and each has adopted a unique approach to addressing the underlying causes of the disease. Orchestra Therapeutic’s NeuroVax targets three proteins expressed on T-cell receptors whilst Opexa Therapeutics’ Tovaxin uses attenuated autologous cells to stimulant an immune response. Bayhill Therapeutics is developing BHT-3009, a tolerising DNA vaccine. All vaccines are in Phase II development and could reach market by 2012.
Key MS questions answered:
— What is the estimated global population for MS in 2014 and what % will be diagnosed and treated?
— Which off-patent MS treatments are resistant to generic competition?
— Will Biogen Idec, Teva and Merck KGaA be able to defend their leading positions in 5 years time?
— There are 7 late-phase pipeline products which target the underlying cause of MS – what are their strengths and weaknesses?
Key Topics Covered: - EXECUTIVE SUMMARY - THE FACTS - PATIENT STATISTICS - PATIENT MODEL - DRUG GROWTH DRIVERS - DRUG GROWTH RISKS/DAMPENERS - THE MS MARKET - CURRENT MS TREATMENTS - GLOBAL SALES FORECASTS OF CURRENT TREATMENTS 2007A-2014E - ANALYSIS OF PHASE III DRUGS - GLOBAL SALES FORECASTS OF PHASE III MS DRUGS 2009E-2014E - ANALYSIS OF PHASE II DRUGS - GLOBAL SALES FORECASTS OF PHASE II MS DRUGS 2011E - 2014E - COMPETITOR RATIO ANALYSIS - COMPETITOR RATIO ANALYSIS - PRODUCTS - COMPETITOR RATIO ANALYSIS - COMPANIES - WINNERS & LOSERS - DISCONTINUATION OF DRUGS - MS GLOSSARY - MS REFERENCES - ACRONYMNS Key Products Analysed and Forecast: - BG-12 - Biogen Idec - Campath - Bayer - Fingolimod - Novartis - Lacquinimod - Teva - MBP 8298 - BioMS/Lilly - Mylinax - Merck KGaA - Teriflunomide - sanofi-aventis - Neurelan - Elan/Acorda
For more information visit http://www.researchandmarkets.com/research/f0d42d/cns_drug_discoveri
Source: Espicom Business Intelligence Ltd